Zura Bio Ltd. Files S-1 for Public Offering

TL;DR

Zura Bio just filed its S-1, get ready for potential IPO action.

AI Summary

Zura Bio Ltd. filed an S-1 form on May 24, 2024, detailing its business operations and financial status. The company, formerly JATT Acquisition Corp, is in the biological products sector and is incorporated in E9 with its fiscal year ending December 31. Zura Bio Ltd. is seeking to raise capital through this filing, with its principal executive offices located in La Jolla, California.

Why It Matters

This S-1 filing provides crucial information for investors and the public regarding Zura Bio Ltd.'s financial health, business strategy, and potential risks as it moves towards becoming a publicly traded company.

Risk Assessment

Risk Level: medium — As a company in the biological products sector undergoing an S-1 filing, Zura Bio faces inherent risks related to clinical trials, regulatory approvals, and market competition.

Key Numbers

• 43,593,678 — Shares (Likely related to share count or potential offering size)
• 13,510,415 — Shares (Another share-related number, possibly outstanding or offered)

Key Players & Entities

• Zura Bio Ltd (company) — Filer of the S-1 document
• JATT Acquisition Corp (company) — Former name of Zura Bio Ltd
• 20240524 (date) — Date of filing
• La Jolla, CA (location) — Location of business and mailing address
• 858-247-0520 (phone_number) — Business phone number

FAQ

Key Financial Figures

• $0.0001 — man Islands exempted company, par value $0.0001 per share ("Class A Ordinary Shares"),
• $5.64 — r Class A Ordinary Shares on Nasdaq was $5.64. See "Risk FactorsSales and issuances o
• $0.001 — ns ordinary shares of Holdco, par value $0.001 per share. " Initial Shareholders " me
• $11.50 — whole warrant exercisable at a price of $11.50 per share. " SEC " means the U.S. Secu

Filing Documents

• zura-20240331xs1.htm (S-1) — 4049KB
• zura-20240331xex5d1.htm (EX-5.1) — 82KB
• zura-20240331xex23d1.htm (EX-23.1) — 4KB
• zura-20240331xexfees.htm (EX-FILING FEES) — 21KB
• zura-20240331xs1006.jpg (GRAPHIC) — 56KB
• zura-20240331xs1007.jpg (GRAPHIC) — 38KB
• zura-20240331xs1008.jpg (GRAPHIC) — 46KB
• zura-20240331xs1009.jpg (GRAPHIC) — 7KB
• zura-20240331xs1010.jpg (GRAPHIC) — 46KB
• zura-20240331xs1011.jpg (GRAPHIC) — 94KB
• zura-20240331xex5d1001.jpg (GRAPHIC) — 3KB
• 0001410578-24-000964.txt ( ) — 16656KB
• zura-20240331.xsd (EX-101.SCH) — 107KB
• zura-20240331_cal.xml (EX-101.CAL) — 78KB
• zura-20240331_def.xml (EX-101.DEF) — 609KB
• zura-20240331_lab.xml (EX-101.LAB) — 659KB
• zura-20240331_pre.xml (EX-101.PRE) — 971KB
• zura-20240331xs1_htm.xml (XML) — 1951KB

USE OF PROCEEDS

USE OF PROCEEDS 58

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 59

BUSINESS

BUSINESS 76 MANAGEMENT 103 EXECUTIVE AND DIRECTOR COMPENSATION 110 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 120 PRINCIPAL SHAREHOLDERS 123 SELLING SECURITYHOLDERS 126

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 130 PLAN OF DISTRIBUTION 138 LEGAL MATTERS 141 EXPERTS 141 WHERE YOU CAN FIND MORE INFORMATION 141 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 i Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the "SEC") using a "shelf" registration process. Under this shelf registration process, the Selling Securityholders may, from time to time, issue, offer and sell, as applicable, any combination of the Class A Ordinary Shares described in this prospectus in one or more offerings from time to time through any means described in the section titled " Plan of Distribution ." We will not receive any proceeds from the sale of the Class A Ordinary Shares by the Selling Securityholders. This prospectus also relates to the issuance by us of Class A Ordinary Shares issuable upon the exercise of any 2024 Pre-Funded Warrants. We will not receive any proceeds from the sale of Class A Ordinary Shares underlying the 2024 Pre-Funded Warrants pursuant to this prospectus, except with respect to amounts received by us upon the exercise of the 2024 Pre-Funded Warrants for cash. A prospectus supplement may also add, update, or change information included in this prospectus. Any statement contained in this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in such prospectus supplement modifies or supersedes such statement. Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded will be deemed not to constitute a part of this prospectus. You should rely only on the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. See " Where You Can Find More Information ." Neither we nor the Selling Securityholders have authoriz

View Full Filing

View this S-1 filing on SEC EDGAR